Pharmaceuticals (commercial-stage) - R&D Tax Benchmark
What proportion of total business expenses do Australian pharmaceuticals (commercial-stage) typically claim as R&D under the RDTI?
What drives R&D intensity in this sector
Once products are on-market, sales, distribution and manufacturing dilute R&D intensity. Reformulation and next-generation pipeline drives what remains.
Sector disclaimer
Mature pharma businesses commonly land in the teens. Higher percentages usually indicate either an active pipeline cohort or a pre-commercial subsidiary structure.
ATO & AusIndustry context
Bioequivalence and routine reformulation often fall outside eligible R&D unless genuine technical uncertainty is documented.
Estimate your own RDTI offset
Plug your turnover, total expenses and notional R&D deductions into our free estimator and benchmark them against this sector range automatically.
Open the offset estimatorMore benchmarks in Healthcare & Medical
Educational benchmark only - not an eligibility test or tax advice. Final eligibility depends on whether your activities meet the s.355-25 / s.355-30 core and supporting R&D definitions and is determined by AusIndustry on registration.